CRESPA trial pts (Golimumab in monoRx peripheral SpA) offered change to MTX. 25/60 pSpA entered the step-down to MTX, but 21/25 flared & 4 (16%) stayed in remission (others restarted GOL). MTX cant maintain GOL remission in pSpA https://t.co/zGg3UqoDqp